“The outlook revision reflects our view of EJGH’s heightened operating losses in fiscal years 2014 and 2015 along with some weakening of unrestricted reserves,” said S&P analyst Suzie Desai.
More articles on healthcare finance:
Prescription drug costs around the globe
2 lawyers weigh in on OIG report putting spotlight on provider-based billing
Cerner adds new revenue cycle leadership: 5 questions with Cerner president, new SVP of RCM
